Clinical implications of chromosomal aberrations (13q14 and 17p13 deletion, translocation t(4;14) and 1q21 amplification) in patients with relapsed multiple myeloma treated by thalidomide or bortezomib (Velcade)
| Authors | |
|---|---|
| Year of publication | 2007 |
| Type | Article in Proceedings |
| Conference | From cell sorting to plasma cell identification and chromosomal aberrations in multiple myeloma – Application manual |
| MU Faculty or unit | |
| Citation | |
| Field | Genetics and molecular biology |
| Keywords | Multiple myeloma; CKS1B amplification; RB deletion; p53 deletion; t(4;14); cIg FISH |
| Description | The aim of the work was: 1) To study the incidence of the chromosomal aberrations known as adverse prognostic factors in MM - deletion of 13q14 (RB1), deletion of 17p13 (p53), amplification of 1q21 (CKS1B) and translocation t(4;14) in a group of 40 patients with relapsed MM. 2) To compare the prognostic and predictive significance of these unfavorable chromosomal aberrations in patients with relapsed MM treated with thalidomide or bortezomib (Velcade) based regimens. |
| Related projects: |